AI could predict who responds to esophageal cancer therapy

NCT ID NCT07063901

Recruiting now Knowledge-focused Sponsor: Central South University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This study uses artificial intelligence to analyze patient data—like medical history, scans, and lab results—to predict how well esophageal cancer patients respond to chemoimmunotherapy before surgery. Researchers aim to build a model that identifies who achieves a complete response and who may need a different approach. The study involves 200 participants and is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors identify which patients benefit most from chemoimmunotherapy before surgery, avoiding ineffective treatments.
What could go wrong: This is an observational study, not a treatment trial. The AI model may not be accurate enough for real-world use, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGUS CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGUS CANCER

Contacts and locations

Locations

The Second Xiangya Hospital of Central South University
RECRUITING

Changsha, Hunan, 410011, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.